Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.3.0.814
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Oct. 31, 2015
Oct. 31, 2014
Revenues:    
Clinical laboratory services $ 17,090 $ 15,822
Product revenues 7,687 8,002
Royalty and license fee income 400 1,000
Total revenues 25,177 24,824
Operating expenses:    
Cost of clinical laboratory services 10,332 10,130
Cost of product revenues 3,611 3,695
Research and development 867 791
Selling, general, and administrative 10,225 10,285
Provision for uncollectible accounts receivable 704 541
Legal fee expense 1,601 2,466
Legal settlements, net (6,800)  
Total operating expenses 20,540 27,908
Operating income (loss) 4,637 (3,084)
Other income (expense):    
Interest (40) (69)
Other 54 19
Foreign exchange loss (130) (472)
Income (loss) before income taxes 4,521 (3,606)
Provision for income taxes (87) (123)
Net income (loss) $ 4,434 $ (3,729)
Net income (loss) per common share:    
Basic (in Dollars per share) $ 0.10 $ (0.08)
Diluted (in Dollars per share) $ 0.10 $ (0.08)
Weighted average common shares outstanding:    
Basic (in Shares) 46,068 44,564
Diluted (in Shares) 46,193 44,564